Eli Lilly is set to acquire three vaccine developers for the sum of $4 billion, according to a report from the Wall Street Journal on Tuesday, The US-based pharmaceutical firm will undertake the acquisition of Curevo, Limmatech and Vaccine Co, in order to consolidate its vaccine and infectious disease treatment portfolio.
"These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences," Daniel M. Skovronsky, M.D., Ph.D., chief scientific and product officer, and president, Lilly Research Laboratories said, according to a press release from the company.
"Decades of evidence now link common infections to diseases that potentially emerge years later, including neurological disease, cancer and infertility. And as antimicrobial resistance erodes our ability to treat bacterial infections, vaccines are increasingly the only path to prevention. Combining these companies' platforms and teams with Lilly's global scale positions us to change that trajectory." Skovronsky added.
(This is a developing story.)
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.